<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="letter"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Clin Hypertens</journal-id><journal-id journal-id-type="iso-abbrev">Clin Hypertens</journal-id><journal-title-group><journal-title>Clinical Hypertension</journal-title></journal-title-group><issn pub-type="epub">2056-5909</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">29234523</article-id><article-id pub-id-type="pmc">5719742</article-id><article-id pub-id-type="publisher-id">82</article-id><article-id pub-id-type="doi">10.1186/s40885-017-0082-0</article-id><article-categories><subj-group subj-group-type="heading"><subject>Letter to the Editor</subject></subj-group></article-categories><title-group><article-title>Amlodipine Vs. hydrochlorothiazide: is there any disparity in its antihypertensive effect or not?</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-6684-7739</contrib-id><name><surname>Jonnalagadda</surname><given-names>Venu Gopal</given-names></name><address><email>gopalvenu63@gmail.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Choudhary</surname><given-names>Kanchan</given-names></name><address><email>choudharykanchan2389@gmail.com</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Matety</surname><given-names>Vijay Kranti</given-names></name><address><email>vijaykranti.mateti@gmail.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1775 2612</institution-id><institution-id institution-id-type="GRID">grid.464627.5</institution-id><institution>Department of Pharmacology &#x00026; Toxicology, National Institute of Pharmaceutical Education and Research, </institution></institution-wrap>Bhangagarh, Guwahati, Assam 781006 India </aff><aff id="Aff2"><label>2</label>Department of Pharmacology &#x00026; Toxicology, Bhupal Nobles&#x02019; Institute Of Pharmaceutical Sciences, Udaipur, Rajasthan 313001 India </aff></contrib-group><pub-date pub-type="epub"><day>6</day><month>12</month><year>2017</year></pub-date><pub-date pub-type="pmc-release"><day>6</day><month>12</month><year>2017</year></pub-date><pub-date pub-type="collection"><year>2017</year></pub-date><volume>23</volume><elocation-id>27</elocation-id><history><date date-type="received"><day>6</day><month>11</month><year>2017</year></date><date date-type="accepted"><day>23</day><month>11</month><year>2017</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s). 2017</copyright-statement><license license-type="OpenAccess"><license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><p id="Par1">We have read the article &#x0201c;Comparison of effects between calcium channel blocker and diuretics in combination with angiotensin II receptor blocker on 24-h central blood pressure and vascular hemodynamic parameters in hypertensive patients: study design for a multicenter, double-blinded, active controlled, phase 4, randomized trial&#x0201d; by GC Oh., et al. and found it quite interesting to learn the testing of effectiveness between amlodipine and hydrochlorothiazide in combination with losartan. After 4&#x000a0;weeks of therapy, non-responders were exposed for dose titration of losartan/amlodipine 100/5&#x000a0;mg daily or losartan/hydrochlorothiazide 100/25&#x000a0;mg daily. However, authors didn&#x02019;t increase in the amlodipine dose from 5 to 10&#x000a0;mg from randomization. However, as per literature both drugs are non-significant in their blood pressure lowering effect. The clarification on above point will further allay the efficacy concerns of clinicians and result in wider usage of future published data.</p></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Hypertension</kwd><kwd>Calcium channel blockers</kwd><kwd>Thiazide diuretics</kwd><kwd>ARB blockers</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2017</meta-value></custom-meta></custom-meta-group></article-meta></front><body><p id="Par2">Dear Editor,</p><p id="Par3">We have read the article <bold>&#x0201c;Comparison of effects between calcium channel blocker and diuretics in combination with angiotensin II receptor blocker on 24-h central blood pressure and vascular hemodynamic parameters in hypertensive patients: study design for a multicenter, double-blinded, active controlled, phase 4, randomized trial&#x0201d;</bold> by GC Oh., et al. and found it quite interesting to learn the testing of effectiveness between amlodipine and hydrochlorothiazide in combination with losartan [<xref ref-type="bibr" rid="CR1">1</xref>].</p><p id="Par4">In study design, the authors presented that, patients will undergo 4&#x000a0;weeks open labeled run in period followed by eligible patients randomized to either losartan/amlodipine 50/5&#x000a0;mg daily or losartan/ hydrochlorothiazide 50/12.5&#x000a0;mg daily for those who are having mean sitting systolic blood pressure (msSBP) &#x02265;&#x02009;140&#x000a0;mmHg. After 4&#x000a0;weeks of therapy, non-responders were exposed for dose titration of losartan/amlodipine 100/5&#x000a0;mg daily or losartan/hydrochlorothiazide 100/25&#x000a0;mg daily. However, authors didn&#x02019;t increase in the amlodipine dose from 5 to 10&#x000a0;mg.</p><p id="Par5">In the AB Adolphe et al., at the end of week 12, the mean reductions for supine and standing systolic and diastolic blood pressure values with amlodipine 2.5 to 10&#x000a0;mg were &#x02212;15.2/&#x02212;12.3&#x000a0;mmHg and &#x02212;14.0/&#x02212;11.6&#x000a0;mmHg respectively, as compared to &#x02212;15.5/&#x02212;11.1&#x000a0;mmHg and &#x02212;16.1/&#x02212;10.1&#x000a0;mmHg after treatment with hydrochlorothiazide25&#x02013;100&#x000a0;mg with comparable efficacy between both groups [<xref ref-type="bibr" rid="CR2">2</xref>]. In another study presented by Tanaka N et al., amlodipine and hydrochlorothiazide decreased both systolic and diastolic blood pressure in both groups, but didn&#x02019;t show any significant difference between both arms after 8&#x000a0;weeks [<xref ref-type="bibr" rid="CR3">3</xref>].</p><p id="Par6">After analyzing the above data from the study by GC Oh et al.; it was spotted that escalating the dose in one arm cannot signify its superiority over the other. Here in this study the dose for hydrochlorothiazide was escalated from 12.5 to 25&#x000a0;mg whereas the dose for amlodipine lingered same i.e. 5&#x000a0;mg.</p><p id="Par7">Published literatures worldwide are of great help for physicians in going ahead to improve their prescription writing. Their baskets of knowledge are enhanced by these basic findings and hence without maintaining a parallel relationship between the two arms, it will not be reasonable to conclude the superiority of losartan/hydrochlorothiazide over losartan/ amlodipine.</p><p id="Par8">The clarification on above point will further allay the efficacy concerns of clinicians and result in wider usage of future published data.</p></body><back><ack><title>Acknowledgements</title><p>The authors would like to thank to almighty and parents for their support.</p><sec id="FPar1"><title>Funding</title><p id="Par9">There is no funding for this work.</p></sec><sec id="FPar2"><title>Availability of data and materials</title><p id="Par10">There is no supporting data for this publication.</p></sec></ack><notes notes-type="author-contribution"><title>Authors&#x02019; contributions</title><p>VG conceptualizes the idea and KC and VK prepared the manuscript with their technical acumen. All authors read and approved the final manuscript.</p></notes><notes notes-type="COI-statement"><sec id="FPar3"><title>Ethics approval and consent to participate</title><p id="Par11">Not applicable</p></sec><sec id="FPar4"><title>Consent for publication</title><p id="Par12">Not applicable</p></sec><sec id="FPar5"><title>Competing interests</title><p id="Par13">The authors declare that they have no competing interests.</p></sec><sec id="FPar6"><title>Publisher&#x02019;s Note</title><p id="Par14">Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></sec></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>GC</surname><given-names>O</given-names></name><name><surname>Lee</surname><given-names>HY</given-names></name><name><surname>Chung</surname><given-names>WJ</given-names></name><name><surname>Youn</surname><given-names>HJ</given-names></name><name><surname>Cho</surname><given-names>EJ</given-names></name><name><surname>Sung</surname><given-names>KC</given-names></name><etal/></person-group><article-title>Comparison of effects between calcium channel blocker and diuretics in combination with angiotensin II receptor blocker on 24-h central blood pressure and vascular hemodynamic parameters in hypertensive patients: study design for a multicenter, double-blinded, active-controlled, phase 4, randomized trial</article-title><source>Clin Hypertens</source><year>2017</year><volume>23</volume><fpage>18</fpage><pub-id pub-id-type="doi">10.1186/s40885-017-0074-0</pub-id><pub-id pub-id-type="pmid">28879040</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adolphe</surname><given-names>AB</given-names></name><name><surname>Vlachakis</surname><given-names>ND</given-names></name><name><surname>Rofman</surname><given-names>BA</given-names></name><name><surname>Brescia</surname><given-names>D</given-names></name><name><surname>Zellner</surname><given-names>SR</given-names></name></person-group><article-title>Long-term open evaluation of amlodipine vs hydrochlorothiazide in patients with essential hypertension</article-title><source>Int J Clin Pharmacol Res</source><year>1993</year><volume>13</volume><fpage>203</fpage><lpage>210</lpage><pub-id pub-id-type="pmid">8150546</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tanaka</surname><given-names>N</given-names></name><name><surname>Babazono</surname><given-names>T</given-names></name><name><surname>Tanaka</surname><given-names>M</given-names></name><name><surname>Shimada</surname><given-names>Y</given-names></name><name><surname>Tomonaga</surname><given-names>O</given-names></name><name><surname>Uchigata</surname><given-names>Y</given-names></name></person-group><article-title>Antihypertensive and metabolic effects of hydrochlorothiazide versus amlodipine when added to losartan in patients with type 2 diabetes</article-title><source>Diabetol Int</source><year>2016</year><volume>7</volume><fpage>266</fpage><lpage>273</lpage><pub-id pub-id-type="doi">10.1007/s13340-015-0243-x</pub-id></element-citation></ref></ref-list></back></article>